SML3976
Apremilast
≥98% (HPLC)
Synonym(s):
(S)-N-{2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methanesulphonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}acetamide, CC 10004, CC-10004, CC10004, N-[2-[(1S)-1-(3-Ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]acetamide
Select a Size
About This Item
Quality Segment
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
-10 to -25°C
SMILES string
[S](=O)(=O)(C[C@@H](N2C(=O)c3c(cccc3NC(=O)C)C2=O)c1cc(c(cc1)OC)OCC)C
InChI
1S/C22H24N2O7S/c1-5-31-19-11-14(9-10-18(19)30-3)17(12-32(4,28)29)24-21(26)15-7-6-8-16(23-13(2)25)20(15)22(24)27/h6-11,17H,5,12H2,1-4H3,(H,23,25)/t17-/m1/s1
InChI key
IMOZEMNVLZVGJZ-QGZVFWFLSA-N
Biochem/physiol Actions
Apremilast (CC-10004) is an orally active, potent and selective phosphodiesterase 4 (PDE4) inhibitor (IC50 = 20/49/50/30 nM with recombinant human PDE4A4/B2/C2/D3 and 1 μM cAMP; no significant PDE1/2/3/5/7/8/9/10/11 inhibition at 10 μM). Apremilast effectively inhibits LPS-induced cytokine and chemokine protein expression from purified human PBMCs (TNFα/IFNγ/IL12 IC50 = 13/110/120 nM, IP10/MIG/MIP1α IC50 = 10/28/40 nM) in vitro and exhibits therapeutic efficacy in a psoriasis mouse model in vivo (2.5/mg/kg b.i.d. p.o.)
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Repr. 2 - STOT SE 2
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.